Primary prevention measures are limited for immunocompetent individuals. Travellers should limit exposure to outdoor dust in endemic areas; during dust storms, they should stay inside and close windows. Air filtration measures can be used indoors.[8]Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections and diseases - coccidioidomycosis/valley fever. May 2023 [internet publication].
https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/coccidioidomycosis-valley-fever
Patients with HIV who live in or visit endemic areas are particularly encouraged to heed the above advice, as well as to avoid long periods of exposure to disturbed native soil (e.g., at building excavation sites).[23]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Coccidioidomycosis. 2021 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/coccidioidomycosis?view=full
Serological testing for coccidioidomycosis is advised in patients with HIV who have previously travelled to or lived in endemic areas.[23]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Coccidioidomycosis. 2021 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/coccidioidomycosis?view=full
Annual to bi-annual testing should be considered for those currently living in endemic areas.[23]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Coccidioidomycosis. 2021 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/coccidioidomycosis?view=full
Primary prophylaxis with fluconazole is indicated for HIV-positive patients with a positive serological test for coccidioidomycosis; CD4 counts <250 cells/mm³; and an absence of signs, symptoms, or laboratory abnormalities compatible with coccidioidal disease.[23]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Coccidioidomycosis. 2021 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/coccidioidomycosis?view=full
Primary prophylaxis can be discontinued when the patient’s CD4 count is ≥250 cells/mm³ and when viral suppression is documented.[23]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Coccidioidomycosis. 2021 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/coccidioidomycosis?view=full
For patients with CD4 counts already ≥250/mm³ and with viral suppression on antiretrovirals, primary prophylaxis with antifungal therapy is not indicated and only close clinical follow-up is recommended.[23]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Coccidioidomycosis. 2021 [internet publication].
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/coccidioidomycosis?view=full